According to people close to the situation, Takeda is considering selling Shire’s eye care business, including the dry eye disease treatment Xiidra (lifitegrast), once it completes the purchase of the company, Bloomberg reported.
The sources noted that the move would be taken to reduce debt raised to fund the $62-billion acquisition, which is expected to close in the first half of 2019.
The people added that Takeda is also weighing a possible sale of Shire’s recombinant human parathyroid hormone Natpara, which is used to control low blood calcium levels related to decreased parathyroid hormone. According to the sources, the potential divestments could raise between $4 billion and $5 billion for Takeda, although discussions around the plans are at an early stage.
Shortly after reaching the deal to buy Shire, Takeda CEO Christophe Weber said that the drugmaker will pursue the large spending cuts needed to make the purchase viable without affecting innovation. Earlier this week, Takeda indicated that it plans to close its US office in Deerfield, Illinois, and move to the Boston area, with work performed at the former site progressively transferred to Massachusetts after the purchase of Shire is finalized.